Pomalidomide-d3
Based on 1 Customer Validation
Pomalidomide-d3 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.0%
- No. CAS: 2093128-28-8
- Fòrmula: C13H8D3N3O4
- Peso molecular:276.27
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
|
Cereblon |
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
No. CAS 2093128-28-8
-
Unlabeled Cas 19171-19-8
-
Appearance Solid
-
Peso molecular 276.27
-
Fòrmula C13H8D3N3O4
-
Color Light yellow to yellow
-
SMILES
O=C1N(C2C(NC(CC2)=O)=O)C(C3=C(N)C([2H])=C([2H])C([2H])=C31)=O
-
Synonyms
CC-4047-d3
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 50 mg/mL (180.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Zhu YX, et al. Molecular mechanism of action of the immune-modulatory drugs, thalidomide, lenalidomide and pomalidomide in multiple myeloma. Leuk Lymphoma. 2013 Apr;54(4):683-7. [Content Brief]
[3]. Hernandez-Ilizaliturri FJ1, et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005 Aug 15;11(16):5984-92. [Content Brief]
[4]. Schafer PH, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003 Jun;305(3):1222-32. [Content Brief]
[5]. Li Z, et al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013 Aug 5;8(8):e71754. [Content Brief]
[6]. Lu J, et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chem Biol. 2015 Jun 18;22(6):755-63. [Content Brief]
[7]. Liu D, et al. Tumour necrosis factor-α inhibits hepatic lipid deposition through GSK-3β/β-catenin signaling in juvenile turbot (Scophthalmus maximus L.). Gen Comp Endocrinol. 2016 Mar 1;228:1-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6196 mL | 18.0982 mL | 36.1965 mL | 90.4912 mL |
| 5 mM | 0.7239 mL | 3.6196 mL | 7.2393 mL | 18.0982 mL | |
| 10 mM | 0.3620 mL | 1.8098 mL | 3.6196 mL | 9.0491 mL | |
| 15 mM | 0.2413 mL | 1.2065 mL | 2.4131 mL | 6.0327 mL | |
| 20 mM | 0.1810 mL | 0.9049 mL | 1.8098 mL | 4.5246 mL | |
| 25 mM | 0.1448 mL | 0.7239 mL | 1.4479 mL | 3.6196 mL | |
| 30 mM | 0.1207 mL | 0.6033 mL | 1.2065 mL | 3.0164 mL | |
| 40 mM | 0.0905 mL | 0.4525 mL | 0.9049 mL | 2.2623 mL | |
| 50 mM | 0.0724 mL | 0.3620 mL | 0.7239 mL | 1.8098 mL | |
| 60 mM | 0.0603 mL | 0.3016 mL | 0.6033 mL | 1.5082 mL | |
| 80 mM | 0.0452 mL | 0.2262 mL | 0.4525 mL | 1.1311 mL | |
| 100 mM | 0.0362 mL | 0.1810 mL | 0.3620 mL | 0.9049 mL |
Pomalidomide-d3 Related Classifications
HY-10984S1 Related Classifications
Powered by Bioz